miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 11, 2026

Is It Too Late To Consider AstraZeneca (LSE:AZN) After Its 54.8% One-Year Surge?

View original at finance.yahoo.com
“For AstraZeneca, the latest twelve month Free Cash Flow (FCF) is about US$9.49b. ... AZN Discounted Cash Flow as at Apr 2026”
Verbatim excerpt from the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The DCF model arrives at an estimated intrinsic value of US$238.68 per share for AstraZeneca

    60% confidence

  • AstraZeneca's DCF analysis suggests the stock is undervalued by 36.2%

    60% confidence

  • AstraZeneca has a valuation score of 3 out of 6

    60% confidence

Data points we hold from this source

AstraZeneca AB · stock return 30day5.2 percent
AstraZeneca AB · stock return 1year54.8 percent
AstraZeneca AB · free cash flow9.49 USD
AstraZeneca AB · stock return ytd12.1 percent
AstraZeneca AB · projected free cash flow20.16 USD
AstraZeneca AB · valuation score3 out_of_6
AstraZeneca AB · intrinsic value dcf238.68 USD
AstraZeneca AB · stock return 7day-0.6 percent
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Is It Too Late To Consider AstraZeneca (LSE:AZN) After Its 54.8% One-Year Surge? — Source | Via News | es.VIA.NEWS